What Happened to Concerns About Human Enhancement?
By R. Jean Cadigan, Margaret Waltz, Rebecca Walker, Rami Major and Incidental Enhancements Research Group,
The Hastings Center: Bioethics Forum
| 04. 25. 2023
Prominent science policy reports that set the stage for the recent Third International Summit on Human Genome Editing all raise questions about human enhancement. Enhancement concerns also consistently loom large in public attitudes on possible uses of these genomic technologies. It may seem surprising, then, that enhancement received little formal attention at the Summit. Instead, the Summit focused elsewhere–on issues of access to emerging forms of somatic cell genome editing for genetic disease. Here we report our observations on the Summit’s de-emphasis of enhancement questions and suggest some consequences of continuing this trend in subsequent science policy deliberations.
Despite its absence from the Summit’s agenda, the topic of genome editing for human enhancement did spontaneously bubble up at the meeting in interesting ways. On the first day, outside the Summit’s venue, London’s Francis Crick Institute, protesters passed out pamphlets titled “Stop Designer Babies.” At first it seemed as if the protest would succeed in making enhancement an important topic at the Summit. In the opening session, Robin Lovell-Badge, chair of the Summit’s organizing committee, referenced the protesters and also noted...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...